markets

Nia Warfield8/5/25

CRISPR shares fall after gene-editing company’s Q2 falls short of estimates

Shares of CRISPR Therapeutics slid 4% Monday after the Swiss biotech missed Wall Street’s Q2 expectations after the bell Monday, despite growing excitement around its flagship gene-editing therapy.

CRISPR posted a wider-than-expected loss of $2.40 per share, compared to the $1.40 loss forecast by analysts polled by FactSet. Revenue climbed 71% year over year to $900,000 but still came in way below the Street’s forecast of $6.1 million.

For investors, all eyes are on Casgevy, the company’s headline therapy and the first FDA-approved treatment using CRISPR/Cas9 gene editing. Casgevy treats rare diseases like sickle cell and transfusion-dependent beta thalassemia. Casgevy is now available at more than 75 treatment centers around the world, hitting its rollout goal and opening the door for more patients to get access.

Though CRISPR codeveloped Casgevy with Vertex Pharmaceuticals, Vertex books the revenue. It reported $30.4 million in Casgevy sales this quarter, up about 114% from the previous quarter.

Despite the earnings miss, CRISPR shares are still up over 43% year to date.

More Markets

See all Markets

Wall Street analysts love Micron’s earnings. The market already loved them too much ahead of time.

A “sell the news” event.

People interact at the Micron booth at the 3rd China...

markets

J. Edward Moreno3h

Canopy rallies after CEO stock purchase

Canopy Growth rallied on Wednesday after its CEO, Luc Mongeau, disclosed an unplanned stock purchase on Tuesday.

Mongeau, who joined Canopy from Mars in January, bought 27,469 shares at CA$1.84. The buy is worth about US$36,259.

It has been a tumultuous time for cannabis stocks, as the market in Canada (where Canopy is located) stagnates and cannabis reform in the US has yet to move forward.

markets

Matt Phillips3h

Robinhood, new S&P 500 leader, the subject of favorable analyst chatter

Robinhood Markets briefly touched a new all-time intraday high in early trading after the newly minted — and now top-performing — member of the the S&P 500 received some favorable write-ups from Wall Street analysts.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions. I own stock as part of my compensation.)

Piper Sandler analysts highlighted momentum in the company’s prediction markets business thanks to the rollout of contracts on college and profession football, noting that the event contracts business was running at a $200 million annualized rate so far in September. They raised their price target on the shares to $140 from $120.

“Prediction Markets (aka event contracts) present significant upside opportunity for Robinhood,” Piper Sandler’s Patrick Moley wrote.

Elsewhere, Citi analysts raised their Q3 and full-year 2025 estimates and upped their price target on the shares to $135, but kept a “neutral” rating on the stock.

“While HOOD continues to see solid momentum across the platform, we believe the stock is pricing in much of the growth potential in our view. Given current valuations and where we are in the retail cycle (closer to the highs than the lows from an activity perspective from our viewpoint), we prefer to wait for a more reasonable entry point at present.”

The stock has clearly had a heck of a run.

Through yesterday’s close, Robinhood was up nearly 240% in 2025. Since it was added to the S&P 500 on Monday, it’s now the top performer among the blue chips, trouncing previous leaders Seagate Technology Holdings and Palantir.

markets

J. Edward Moreno4h

UniQure surges after encouraging trial results for Huntington’s treatment

UniQure rose more than 150% in early trading Wednesday after it released trial results that showed its experimental gene therapy for Huntington’s disease slowed its progression by 75% after three years.

The treatment, AMT-130, is a one-time treatment for Huntington’s, a genetic brain disease that degrades cognitive function and muscle control. There is currently no cure for the disease.

UniQure said it plans to submit the treatment for approval to the Food and Drug Administration in the first quarter of 2026, meaning it could become available to patients later that year. The company currently makes nearly all of its revenue from gene therapies that treat hemophilia.

Halo of the sun

A tiny UK company is showing how easy it is to get an (undeserved?) Nvidia halo effect

Step 1: join a free Nvidia program. Step 2: watch stock go up. Step 3: watch stock go down.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.

©2025 Sherwood Media, LLC